Drugs / Recombinant Human Factor VIIa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04543383 | Jul 2020 → Jun 2023 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Beijing Tiantan Biological Products Co., Ltd. | Results 国药天坛蓉生rFⅦa瞬效止血，极速守护生命防线 ——止血更迅速、更有效、更安全 tiantanbio.com ↗
临床止血疗效显著，较同类产品，在止血成功率、每次出血平均给药次数、成功止血时间等指标上具有明显优势。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Beijing Tiantan Biological Products Co., Ltd. | 国药天坛蓉生rFⅦa瞬效止血，极速守护生命防线 ——止血更迅速、更有效、更安全 tiantanbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Factor VIIa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04543383 ↗ |
| Known as | rFVIIa | “Recombinant Human Factor VIIa (rFVIIa)” NCT04543383 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Factor VIIa (rFVIIa)” NCT04543383 ↗ |
| Route | Intravenous | “rFVIIa will be administered intravenously.” NCT04543383 ↗ |